Celgene Corp (CELG) 132.72 $CELG
Watch for Celgene to Potentially Pullback After Gaining 1.25% Yesterday
Comtex SmarTrend(R) - Wed Aug 05, 4:06PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $132.28 to a high of $133.59. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $133.00 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 132.72 (+1.64)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.25% Gain
Comtex SmarTrend(R) - Wed Aug 05, 4:05PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $132.28 to a high of $133.59. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $133.00 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 132.72 (+1.64)
What Company Will Be Fastest Growing Big-Cap Biotech?
at Investor's Business Daily - Wed Aug 05, 1:58PM CDT
While drugs for treating and curing hepatitis C have made one biotech company the envy of the industry, another biotech -- Celgene -- is poised to break ahead of its peer pack over the next few years. Celgene's (CELG) sales and profit growth is seen...
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), GEVA: 238.60 (+2.80), PCYC: 261.25 (+1.70), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), ALXN: 197.94 (+0.79), RCPT: 228.97 (+0.97), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 05, 9:44AM CDT
In the midst of earnings, acquisitions continue to make news with the latest being Shire's proposal for Baxalta (BXLT).
VRTX: 141.22 (+0.92), LXRX: 12.90 (+0.23), VVUS: 1.30 (unch), AMGN: 176.44 (+1.64), BXLT: 37.30 (+0.20), REGN: 592.40 (+11.46), CELG: 132.72 (+1.64)
These 2 Catalysts Helped Push Celgene's Market Value Over $100 Billion in July
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 05, 7:42AM CDT
Shares of biotech behemoth Celgene surged by 13% in July, based on data from S&P Capital IQ , on the heels of two major catalysts. By far the bigger of the two catalysts was the mid-July announcement that Celgene would be acquiring ...
RCPT: 228.97 (+0.97), CELG: 132.72 (+1.64)
Top Mutual Funds Pile In Celgene Other Leading Stocks
at Investor's Business Daily - Tue Aug 04, 5:51PM CDT
IBD's new buys list showed the country's leading stock mutual funds the past three months have continued to gobble up top-rated medical stocks, such as Allergan (AGN), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Molina Healthcare (MOH) and...
ACHC: 82.97 (+5.08), LAD: 119.80 (+0.81), MNST: 154.00 (+2.28), NKE: 116.75 (+0.98), SKX: 160.29 (+6.39), ORLY: 244.17 (+0.80), VFC: 76.72 (+0.49), GOOG: 643.78 (+14.53), MOH: 77.24 (+1.84), CELG: 132.72 (+1.64), SBUX: 59.01 (+0.31), AGN: 336.64 (+5.64), TSS: 47.54 (+0.47), PZZA: 71.45 (-4.16), HAWK: 45.45 (-0.14), ULTA: 167.01 (+1.94), REGN: 592.40 (+11.46)
Large-Cap Growth Mutual Funds Rally In A Choppy July
at Investor's Business Daily - Tue Aug 04, 5:51PM CDT
Large-cap growth mutual funds leaped ahead of peers in a markedly volatile month for U.S. equities in July. Investors shunned risk as worries grew over Greece and China and the earnings season got off to a fitful start. TCW Select Equities , a $1.8...
SBUX: 59.01 (+0.31), PXD: 125.60 (+0.77), V: 74.98 (-0.29), FB: 96.44 (+2.38), HAL: 40.61 (+1.01), RCPT: 228.97 (+0.97), GOOGL: 673.29 (+12.01), CELG: 132.72 (+1.64)
Is Agios (AGIO) Poised to Beat Estimates in Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 11:30AM CDT
We expect Agios Pharmaceuticals, Inc. (AGIO) to beat expectations when it reports second-quarter 2015 results on Aug 6.
MYL: 54.60 (-0.07), AGIO: 111.85 (+0.73), EPZM: 22.29 (+0.14), CELG: 132.72 (+1.64)
Celgene Prices $8 Billion of Senior Unsecured Notes
Business Wire - Tue Aug 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of five series of senior unsecured notes for an aggregate principal amount of $8.0 billion. Of these notes, $1.0 billion will mature in 2018 and will bear interest at an annual rate of 2.125 percent, $1.5 billion will mature in 2020 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2022 and will bear interest at an annual rate of 3.550 percent, $2.5 billion will mature in 2025 and will bear interest at an annual rate of 3.875 percent and $2.0 billion will mature in 2045 and will bear interest at an annual rate of 5.000 percent. The 2.125 percent notes due 2018, the 2.875 percent notes due 2020, the 3.550 percent notes due in 2022, the 3.875 percent notes due in 2025 and the 5.000 percent notes due in 2045 were priced to yield 2.127 percent, 2.914 percent, 3.594 percent, 3.993 percent and 5.020 percent, respectively.
RCPT: 228.97 (+0.97), CELG: 132.72 (+1.64), CELGZ: 2.01 (+0.07)
Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 5:00AM CDT
The biotech sector as a whole has been a mixed performer this earnings season. Let's take a look at how biotech ETFs are responding?
BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), ALXN: 197.94 (+0.79), IBB: 386.72 (+2.91), BBH: 141.62 (+1.00), AMGN: 176.44 (+1.64), CELG: 132.72 (+1.64)
Celgene proposes offering of senior unsecured notes
M2 - Tue Aug 04, 4:38AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) said on Monday that it plans to issue senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission.
CELG: 132.72 (+1.64), CELGZ: 2.01 (+0.07)
Celgene Announces Offering of Senior Unsecured Notes
Business Wire - Mon Aug 03, 7:20AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
RCPT: 228.97 (+0.97), CELG: 132.72 (+1.64), CELGZ: 2.01 (+0.07)
'Fast Money' Recap: Goodbye, July; Will August Be More of the Same?
at The Street - Sat Aug 01, 4:00AM CDT
The trading panel discussed health care, biotech and energy stocks.
VLO: 64.82 (+0.39), TSO: 98.12 (+1.30), GILD: 118.66 (-0.21), XOP: 36.75 (-0.47), PFE: 35.82 (-0.29), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), GDX: 13.09 (-0.20), CVX: 84.03 (-1.18), Z: 72.42 (-1.78), XLE: 67.18 (-0.51), CELG: 132.72 (+1.64)
5 Top Stocks Riding Earnings Season To Big Gains
at Investor's Business Daily - Fri Jul 31, 5:21PM CDT
Earnings season has been unkind to a number of recent leaders like Taser International (TASR), but it has spurred plenty of other stocks to breakouts or big gains. The market uptrend is still under pressure, but these stocks aren't letting that get...
VRX: 262.52 (+2.54), ELLI: 80.98 (-0.20), JAZZ: 191.90 (+1.24), UHS: 143.96 (-2.28), TASR: 25.32 (-0.91), CELG: 132.72 (+1.64)
AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 9:30AM CDT
AstraZeneca's (AZN) second-quarter 2015 core earnings of $1.21 per American Depositary Share were significantly above the Zacks Consensus Estimate of 52 cents.
ISIS: 54.52 (-0.78), AZN: 34.54 (+0.20), CELG: 132.72 (+1.64)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), ABBV: 70.30 (+0.35), CELG: 132.72 (+1.64)
Q2 Earnings Season Halftime Report
ESTMZ - Wed Jul 29, 1:47PM CDT
And just like that, we’re already at the midpoint of the second quarter earnings season. Technically, we’re past that, with 264 S&P 500 companies reporting. As usual, we are in much better standing in regards to growth than we were at the...
VLO: 64.82 (+0.39), SPY: 210.07 (+0.69), GILD: 118.66 (-0.21), FB: 96.44 (+2.38), XOM: 77.17 (unch), CVX: 84.03 (-1.18), TWTR: 28.48 (-0.86), AAPL: 115.40 (+0.76), GOOG: 643.78 (+14.53), CELG: 132.72 (+1.64)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 118.66 (-0.21), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), CELG: 132.72 (+1.64)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 335.41 (+5.03), F: 14.80 (-0.11), RIG: 12.34 (+0.12), GILD: 118.66 (-0.21), PFE: 35.82 (-0.29), COP: 49.12 (-0.75), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), DD: 54.57 (-0.07), CVX: 84.03 (-1.18), SLB: 82.50 (+0.23), UPS: 102.94 (+0.30), CELG: 132.72 (+1.64)
Watch for Celgene to Potentially Pullback After Gaining 1.25% Yesterday
Comtex SmarTrend(R) - Wed Aug 05, 4:06PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $132.28 to a high of $133.59. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $133.00 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 132.72 (+1.64)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.25% Gain
Comtex SmarTrend(R) - Wed Aug 05, 4:05PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $132.28 to a high of $133.59. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $133.00 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 132.72 (+1.64)
What Company Will Be Fastest Growing Big-Cap Biotech?
at Investor's Business Daily - Wed Aug 05, 1:58PM CDT
While drugs for treating and curing hepatitis C have made one biotech company the envy of the industry, another biotech -- Celgene -- is poised to break ahead of its peer pack over the next few years. Celgene's (CELG) sales and profit growth is seen...
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), GEVA: 238.60 (+2.80), PCYC: 261.25 (+1.70), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), ALXN: 197.94 (+0.79), RCPT: 228.97 (+0.97), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 05, 9:44AM CDT
In the midst of earnings, acquisitions continue to make news with the latest being Shire's proposal for Baxalta (BXLT).
VRTX: 141.22 (+0.92), LXRX: 12.90 (+0.23), VVUS: 1.30 (unch), AMGN: 176.44 (+1.64), BXLT: 37.30 (+0.20), REGN: 592.40 (+11.46), CELG: 132.72 (+1.64)
These 2 Catalysts Helped Push Celgene's Market Value Over $100 Billion in July
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 05, 7:42AM CDT
Shares of biotech behemoth Celgene surged by 13% in July, based on data from S&P Capital IQ , on the heels of two major catalysts. By far the bigger of the two catalysts was the mid-July announcement that Celgene would be acquiring ...
RCPT: 228.97 (+0.97), CELG: 132.72 (+1.64)
Top Mutual Funds Pile In Celgene Other Leading Stocks
at Investor's Business Daily - Tue Aug 04, 5:51PM CDT
IBD's new buys list showed the country's leading stock mutual funds the past three months have continued to gobble up top-rated medical stocks, such as Allergan (AGN), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Molina Healthcare (MOH) and...
ACHC: 82.97 (+5.08), LAD: 119.80 (+0.81), MNST: 154.00 (+2.28), NKE: 116.75 (+0.98), SKX: 160.29 (+6.39), ORLY: 244.17 (+0.80), VFC: 76.72 (+0.49), GOOG: 643.78 (+14.53), MOH: 77.24 (+1.84), CELG: 132.72 (+1.64), SBUX: 59.01 (+0.31), AGN: 336.64 (+5.64), TSS: 47.54 (+0.47), PZZA: 71.45 (-4.16), HAWK: 45.45 (-0.14), ULTA: 167.01 (+1.94), REGN: 592.40 (+11.46)
Large-Cap Growth Mutual Funds Rally In A Choppy July
at Investor's Business Daily - Tue Aug 04, 5:51PM CDT
Large-cap growth mutual funds leaped ahead of peers in a markedly volatile month for U.S. equities in July. Investors shunned risk as worries grew over Greece and China and the earnings season got off to a fitful start. TCW Select Equities , a $1.8...
SBUX: 59.01 (+0.31), PXD: 125.60 (+0.77), V: 74.98 (-0.29), FB: 96.44 (+2.38), HAL: 40.61 (+1.01), RCPT: 228.97 (+0.97), GOOGL: 673.29 (+12.01), CELG: 132.72 (+1.64)
Is Agios (AGIO) Poised to Beat Estimates in Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 11:30AM CDT
We expect Agios Pharmaceuticals, Inc. (AGIO) to beat expectations when it reports second-quarter 2015 results on Aug 6.
MYL: 54.60 (-0.07), AGIO: 111.85 (+0.73), EPZM: 22.29 (+0.14), CELG: 132.72 (+1.64)
Celgene Prices $8 Billion of Senior Unsecured Notes
Business Wire - Tue Aug 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of five series of senior unsecured notes for an aggregate principal amount of $8.0 billion. Of these notes, $1.0 billion will mature in 2018 and will bear interest at an annual rate of 2.125 percent, $1.5 billion will mature in 2020 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2022 and will bear interest at an annual rate of 3.550 percent, $2.5 billion will mature in 2025 and will bear interest at an annual rate of 3.875 percent and $2.0 billion will mature in 2045 and will bear interest at an annual rate of 5.000 percent. The 2.125 percent notes due 2018, the 2.875 percent notes due 2020, the 3.550 percent notes due in 2022, the 3.875 percent notes due in 2025 and the 5.000 percent notes due in 2045 were priced to yield 2.127 percent, 2.914 percent, 3.594 percent, 3.993 percent and 5.020 percent, respectively.
RCPT: 228.97 (+0.97), CELG: 132.72 (+1.64), CELGZ: 2.01 (+0.07)
Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 5:00AM CDT
The biotech sector as a whole has been a mixed performer this earnings season. Let's take a look at how biotech ETFs are responding?
BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), ALXN: 197.94 (+0.79), IBB: 386.72 (+2.91), BBH: 141.62 (+1.00), AMGN: 176.44 (+1.64), CELG: 132.72 (+1.64)
Celgene proposes offering of senior unsecured notes
M2 - Tue Aug 04, 4:38AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) said on Monday that it plans to issue senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission.
CELG: 132.72 (+1.64), CELGZ: 2.01 (+0.07)
Celgene Announces Offering of Senior Unsecured Notes
Business Wire - Mon Aug 03, 7:20AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
RCPT: 228.97 (+0.97), CELG: 132.72 (+1.64), CELGZ: 2.01 (+0.07)
'Fast Money' Recap: Goodbye, July; Will August Be More of the Same?
at The Street - Sat Aug 01, 4:00AM CDT
The trading panel discussed health care, biotech and energy stocks.
VLO: 64.82 (+0.39), TSO: 98.12 (+1.30), GILD: 118.66 (-0.21), XOP: 36.75 (-0.47), PFE: 35.82 (-0.29), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), GDX: 13.09 (-0.20), CVX: 84.03 (-1.18), Z: 72.42 (-1.78), XLE: 67.18 (-0.51), CELG: 132.72 (+1.64)
5 Top Stocks Riding Earnings Season To Big Gains
at Investor's Business Daily - Fri Jul 31, 5:21PM CDT
Earnings season has been unkind to a number of recent leaders like Taser International (TASR), but it has spurred plenty of other stocks to breakouts or big gains. The market uptrend is still under pressure, but these stocks aren't letting that get...
VRX: 262.52 (+2.54), ELLI: 80.98 (-0.20), JAZZ: 191.90 (+1.24), UHS: 143.96 (-2.28), TASR: 25.32 (-0.91), CELG: 132.72 (+1.64)
AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 9:30AM CDT
AstraZeneca's (AZN) second-quarter 2015 core earnings of $1.21 per American Depositary Share were significantly above the Zacks Consensus Estimate of 52 cents.
ISIS: 54.52 (-0.78), AZN: 34.54 (+0.20), CELG: 132.72 (+1.64)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), ABBV: 70.30 (+0.35), CELG: 132.72 (+1.64)
Q2 Earnings Season Halftime Report
ESTMZ - Wed Jul 29, 1:47PM CDT
And just like that, we’re already at the midpoint of the second quarter earnings season. Technically, we’re past that, with 264 S&P 500 companies reporting. As usual, we are in much better standing in regards to growth than we were at the...
VLO: 64.82 (+0.39), SPY: 210.07 (+0.69), GILD: 118.66 (-0.21), FB: 96.44 (+2.38), XOM: 77.17 (unch), CVX: 84.03 (-1.18), TWTR: 28.48 (-0.86), AAPL: 115.40 (+0.76), GOOG: 643.78 (+14.53), CELG: 132.72 (+1.64)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 118.66 (-0.21), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), CELG: 132.72 (+1.64)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 335.41 (+5.03), F: 14.80 (-0.11), RIG: 12.34 (+0.12), GILD: 118.66 (-0.21), PFE: 35.82 (-0.29), COP: 49.12 (-0.75), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), DD: 54.57 (-0.07), CVX: 84.03 (-1.18), SLB: 82.50 (+0.23), UPS: 102.94 (+0.30), CELG: 132.72 (+1.64)
